Gecacitinib
Gecacitinib is an oral kinase inhibitor from Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in registered phase 2 trials for cervical cancer.
Overview
Gecacitinib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in cervical cancer. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.
1.Gecacitinib slips into a pocket on its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Gecacitinib" OR ABSTRACT:"Gecacitinib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gecacitinib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentNP137
Shares Cervical cancer and the tags pipeline, registry-only.
- TreatmentVudalimab
Shares Cervical cancer and the tags pipeline, registry-only.
- TreatmentAdavosertib
Shares the tags pipeline, registry-only.
- TreatmentAlisertib
Shares the tags pipeline, registry-only.
- TreatmentAMO959
Shares the tags pipeline, registry-only.
- TreatmentAMT-116
Shares the tags pipeline, registry-only.
- TreatmentARD103
Shares the tags pipeline, registry-only.
- TreatmentAU-007
Shares the tags pipeline, registry-only.